Article
Medicine, Research & Experimental
Tamas Benkoe, Julia Koenig, Jens M. Theysohn, Clemens Schotten, Fuat H. Saner, Juergen Treckmann, Sonia Radunz
Summary: This study compared the recurrence of HCC after liver transplantation following TACE or radioembolization bridging treatment. The results showed no significant difference in HCC recurrence and overall survival between the radioembolization group and TACE group. Multivariable analysis found recipient age, gender, tumor necrosis, and microvascular invasion to be associated with HCC recurrence.
EUROPEAN JOURNAL OF MEDICAL RESEARCH
(2022)
Article
Oncology
Sun Young Yim, Ho Soo Chun, Jae Seung Lee, Ji-Hwan Lim, Tae Hyung Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Gyoung Min Kim, Jong Yun Won, Yeon Seok Seo, Yun Hwan Kim, Soon Ho Um, Do Young Kim
Summary: This study investigated the long-term clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with transarterial radioembolization (TARE) in a multi-medical center in Korea. The results showed that TARE is safe and effective for patients with early to advanced HCC.
Review
Radiology, Nuclear Medicine & Medical Imaging
Frank H. Miller, Camila Lopes Vendrami, Ahmed Gabr, Jeanne M. Horowitz, Linda C. Kelahan, Ahsun Riaz, Riad Salem, Robert J. Lewandowski
Summary: Transarterial radioembolization (TARE) with yttrium 90 is increasingly being used for the treatment of hepatocellular carcinoma (HCC). Initially used as a palliative therapy for advanced HCC, recent advancements have expanded its application to different stages of treatment. Evaluating the therapeutic response to TARE is challenging and requires appropriate tools and methods to optimize treatment outcomes for patients.
Article
Radiology, Nuclear Medicine & Medical Imaging
Elisabeth Dhondt, Bieke Lambert, Laurens Hermie, Lynn Huyck, Peter Vanlangenhove, Anja Geerts, Xavier Verhelst, Maridi Aerts, Aude Vanlander, Frederik Berrevoet, Roberto Ivan Troisi, Hans Van Vlierberghe, Luc Defreyne
Summary: This study compared the efficacy and safety of Y-90 glass TARE and DEB-TACE for unresectable HCC. The results showed that TARE conferred superior tumor control and overall survival compared to DEB-TACE. Both treatments had similar safety profiles.
Article
Medicine, General & Internal
Baran U. Vardar, Ece Meram, Kerim Karaoglu, Muxuan Liang, Menggang Yu, Paul Laeseke, Orhan S. Ozkan
Summary: The safety and efficacy of combining transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) in hepatocellular carcinoma (HCC) patients were evaluated. The study found that the addition of TACE to TARE resulted in improved liver function and significantly longer overall survival and time to progression. This suggests that the combination therapy of TACE and TARE is a safe and effective treatment option for unresectable HCC patients.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Multidisciplinary Sciences
William T. N. Culp, Eric G. Johnson, Michelle A. Giuffrida, Robert B. Rebhun, James K. Cawthra, Heidi A. Schwanz, Jenna H. Burton, Michael S. Kent
Summary: This study describes the use of a novel drug-eluting microsphere in transarterial chemoembolization for dogs with non-resectable hepatic neoplasia. The results show significant reduction in tumor volume and improvement in clinical signs.
Article
Radiology, Nuclear Medicine & Medical Imaging
Juil Park, Dongkyu Oh, Jin Chul Paeng, Myungsu Lee, Jin Wook Chung, Hyo-Cheol Kim
Summary: This study aimed to investigate the impact of radioembolization on contralateral hepatic hypertrophy and liver function in patients with hepatocellular carcinoma. The results showed that patients with contralateral arterioportal shunting may experience worsened liver function and less hypertrophy of the nontarget liver.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
(2022)
Article
Gastroenterology & Hepatology
Ling Li, Yicheng Zhang, Yang Zhou, Haijie Hu, Yizong Hu, Christos Georgiades, Hai-Quan Mao, Florin M. Selaru
Summary: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide. Current therapies for Barcelona Clinic Liver Cancer (BCLC)-B patients have shown minimal improvement in clinical outcomes. This study identified bortezomib (BTZ) as a highly cytotoxic small molecule for HCC and designed sustained release BTZ nanoparticles (BTZ-NP) that showed a release of BTZ over 30 days. In vivo tests demonstrated that BTZ-NP effectively controlled tumor size and improved survival in three animal models, making it a promising localized treatment for HCC.
Article
Engineering, Biomedical
Guorong Jia, Tao Wang, Rou Li, Xiao Li, Gaofeng Sun, Wei Chen, Ye Peng, Chao Cheng, Jijin Yang, Changjing Zuo
Summary: In interventional treatment, the combination therapy of transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) using multifunctional nanoparticles shows promise in overcoming drug resistance and improving therapeutic effect in hepatocellular carcinoma (HCC).
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Multidisciplinary Sciences
Yong Du, Angel Cortez, Anders Josefsson, Mohammadreza Zarisfi, Rebecca Krimins, Eleni Liapi, Jessie R. Nedrow
Summary: This study explores the use of alpha-particle emitting radioembolization for the treatment and monitoring of liver tumors. It successfully demonstrates the in vivo simultaneous multiple-radionuclide SPECT imaging and shows that alpha-particle emitting TARE agent can effectively target liver tumors.
Review
Biotechnology & Applied Microbiology
Gang Yuan, Zhiyin Liu, Weiming Wang, Mengnan Liu, Yanneng Xu, Wei Hu, Yao Fan, Xun Zhang, Yong Liu, Guangyan Si
Summary: Hepatocellular carcinoma (HCC) is a major global health concern with high incidence and mortality rates. Transarterial chemoembolization (TACE) is commonly used for the treatment of unresectable HCC, but its therapeutic effect is often limited. Recent research has focused on using nanomaterials as a drug delivery platform to improve the distribution and bioavailability of drugs in tumor tissues. Functionalized nanomaterials have been developed for targeted embolization, controlled drug release, and real-time imaging, aiming to enhance the therapeutic effect of TACE against HCC.
JOURNAL OF NANOBIOTECHNOLOGY
(2023)
Article
Health Care Sciences & Services
Evgenia Kotsifa, Chrysovalantis Vergadis, Michael Vailas, Nikolaos Machairas, Stylianos Kykalos, Christos Damaskos, Nikolaos Garmpis, Georgios D. Lianos, Dimitrios Schizas
Summary: HCC is the most common primary liver malignancy associated with liver cirrhosis and chronic liver disease. Key risk factors for HCC development include viral infections, alcoholic liver disease, and nonalcoholic fatty liver disease. Treatment options for HCC depend on tumor burden, liver function, and patient's health status, with surgical resection, transplantation, ablation, TACE, and systemic therapy being potential strategies.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Chemistry, Multidisciplinary
Chengrui Zhong, Yi Niu, Wenwu Liu, Yichuan Yuan, Kai Li, Yunxing Shi, Zhiyu Qiu, Keren Li, Zhu Lin, Zhenkun Huang, Dinglan Zuo, Zhiwen Yang, Yadi Liao, Yuanping Zhang, Chenwei Wang, Jiliang Qiu, Wei He, Yunfei Yuan, Binkui Li
Summary: This study identifies S100A9 as a key driver for post-TACE HCC progression by promoting mitochondrial fission and reactive oxygen species production. Higher S100A9 levels are associated with worse prognosis in HCC patients.
Article
Gastroenterology & Hepatology
Riad Salem, Guy E. Johnson, Edward Kim, Ahsun Riaz, Vivian Bishay, Eveline Boucher, Kirk Fowers, Robert Lewandowski, Siddharth A. Padia
Summary: The LEGACY study evaluated the efficacy of yttrium-90 glass microspheres in treating solitary, unresectable HCC <= 8 cm, showing promising response rates and durable responses in a multicenter setting.
Review
Multidisciplinary Sciences
Simon Lemieux, Alex Buies, Alexis F. Turgeon, Julie Hallet, Gaetan Daigle, Francois Cote, Steeve Provencher
Summary: Yttrium-90 transarterial radioembolization did not show significant effects on survival, progression-free survival, time to progression, disease control rate, and incidence of gastro-intestinal ulcers in non-surgical HCC patients, but was associated with significantly lower rates of grade >= 3 adverse events. Further randomized controlled trials are needed to determine optimal treatment.
Meeting Abstract
Oncology
Riad Salem, Mary Frances Mulcahy
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Talia Baker, Parissa Tabrizian, Ivan Zendejas, Thomas Clark Gamblin, Marwan Kazimi, Karim Boudjema, David Geller, Riad Salem
Summary: This document presents expert recommendations based on a multidisciplinary group's experience and consensus, aiming to demonstrate the feasibility and safety of converting borderline-resectable liver cancer patients to surgical options using transarterial radioembolization with yttrium-90. The document also addresses concerns about potential complications associated with this treatment during surgical intervention.
Editorial Material
Cardiac & Cardiovascular Systems
Bartley Thornburg, Ahsun Riaz, Riad Salem
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Marnix Lam, Etienne Garin, Marco Maccauro, S. Cheenu Kappadath, Daniel Y. Sze, Cuneyt Turkmen, Murat Cantasdemir, Paul Haste, Ken Herrmann, Hamad Saleh Alsuhaibani, Matthew Dreher, Kirk D. Fowers, Riad Salem
Summary: This study aimed to investigate the relationship between tumor absorbed dose and clinical outcomes in hepatocellular carcinoma patients. The results showed a significant association between absorbed dose and objective response, overall survival, and alpha fetoprotein response.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Pouya Entezari, Ahmed Gabr, Riad Salem, Robert J. Lewandowski
Summary: Y90 radioembolization has shown favorable results for patients with metastatic colorectal cancer to the liver, but its efficacy in earlier-stage disease is not promising. Radiation segmentectomy, as a novel approach, is suitable for patients with unresectable hepatocellular carcinoma.
INTERNATIONAL JOURNAL OF HYPERTHERMIA
(2022)
Review
Gastroenterology & Hepatology
Maria Reig, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fabrega, Marta Burrel, Angeles Garcia-Criado, Robin K. Kelley, Peter R. Galle, Vincenzo Mazzaferro, Riad Salem, Bruno Sangro, Amit G. Singal, Arndt Vogel, Josep Fuster, Carmen Ayuso, Jordi Bruix
Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.
JOURNAL OF HEPATOLOGY
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Piyush Goyal, Riad Salem, Samdeep K. Mouli
Summary: Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide. While liver transplant is the preferred curative treatment, limited organ supply poses challenges in accessibility and waiting time. As a result, interventional oncology therapies have been used to treat the majority of HCC patients, including those awaiting transplant. The Barcelona Clinic Liver Cancer (BCLC) staging system is widely utilized to guide treatment allocation. The most recent update in November 2021, shaped by expert opinions outside the BCLC group, includes additional treatment options for early-stage disease, further categorization of intermediate disease, and alternative treatments to significantly improve survival in advanced-stage disease. The update also introduces a new staging schema for disease progression and supports treatment stage migration (TSM) within the main staging and treatment algorithm. This article reviews the recent developments in the BCLC guidelines and emphasizes ongoing research, particularly in radioembolization, that will inform future best practices.
BRITISH JOURNAL OF RADIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Riad Salem, Siddharth A. Padia, Marnix Lam, Carlo Chiesa, Paul Haste, Bruno Sangro, Beau Toskich, Kirk Fowers, Joseph M. Herman, S. Cheenu Kappadath, Thomas Leung, Daniel Y. Sze, Edward Kim, Etienne Garin
Summary: This article presents the updated recommendations from the TheraSphere Global Dosimetry Steering Committee for the treatment of hepatocellular carcinoma (HCC). The recommendations aim to provide a more personalized and effective approach to treatment, taking into account disease presentation, tumor biology, and treatment intent.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jules Gregory, Lambros Tselikas, Caroline Allimant, Thierry de Baere, Irene Bargellini, Jon Bell, Jose Ignacio Bilbao, Antoine Bouvier, Julius Chapiro, Carlo Chiesa, Thomas Decaens, Alban Denys, Rafael Duran, Julien Edeline, Etienne Garin, Julien Ghelfi, Thomas Helmberger, Farah Irani, Marnix Lam, Robert Lewandowski, David Liu, Romaric Loffroy, David C. Madoff, Charles Mastier, Riad Salem, Bruno Sangro, Daniel Sze, Valerie Vilgrain, Michael Vouche, Boris Guiu, Maxime Ronot
Summary: This study aimed to define a textbook outcome (TO) for selective internal radiation therapy (SIRT) of hepatocellular carcinoma. The final TO, determined through expert opinions and an international survey, is a multidimensional standardization tool suitable for routine care, clinical round, and research.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Editorial Material
Gastroenterology & Hepatology
Brandon M. Caldwell, Ahmed Gabr, Pouya Entezari, Alex Sher, Edward Kim, Guy E. Johnson, Riad Salem, Robert J. Lewandowski
LIVER TRANSPLANTATION
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Courtney Sperry, Asad Malik, Allison Reiland, Bartley Thornburg, Rajesh Keswani, Muhammed Sufyaan Ebrahim Patel, Aziz Aadam, Anthony Yang, Ezra Teitelbaum, Riad Salem, Ahsun Riaz
Summary: The study evaluated the feasibility, effectiveness, and outcomes of percutaneous cholecystostomy drain internalization in patients with calculous cholecystitis who were not surgical candidates. Dual cholecystoduodenal stent placement was attempted in 17 patients, with successful placement in 13 patients. The 1-year patency rate was 77%.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Andrew M. Chiu, Rohan Savoor, Andrew C. Gordon, Ahsun Riaz, Kent T. Sato, Elias Hohlastos, Riad Salem, Robert J. Lewandowski
Summary: A retrospective study found that yttrium-90 radiation segmentectomy is a safe and effective treatment for oligo-metastatic secondary hepatic malignancies, achieving high disease control rate.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Gabriel M. Knight, Andrew C. Gordon, Vanessa Gates, Abhinav Talwar, Ahsun Riaz, Riad Salem, Robert Lewandowski
Summary: Yttrium-90 transarterial radioembolization (TARE) has evolved from a salvage or palliative therapy to a versatile and potentially curative treatment for liver cancer patients. Personalized radiation dosimetry has been proven to improve tumor response and overall survival while ensuring patient safety. This review covers the imaging techniques, dosimetry methods, and future developments in TARE.
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Riad Salem, Allison Reiland, Bartley Thornburg
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Aakash N. Gupta, Andrew C. Gordon, Ahmed Gabr, Aparna Kalyan, Sheetal M. Kircher, Devalingam Mahalingam, Mary F. Mulcahy, Ryan P. Merkow, Anthony D. Yang, David J. Bentrem, Juan C. Caicedo-Ramirez, Ahsun Riaz, Bartley Thornburg, Kush Desai, Kent T. Sato, Elias S. Hohlastos, Laura Kulik, Al B. Benson, Riad Salem, Robert J. Lewandowski
Summary: The study evaluated the safety, efficacy, and potential for downstaging to resection of yttrium-90 radioembolization for treatment of unresectable intrahepatic cholangiocarcinoma. The results demonstrated high local disease control rates and the therapeutic role of Y90 for unresectable ICC patients who were downstaged to resection, providing a new treatment option.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
(2022)
